Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function

被引:0
|
作者
Giuntoli, RL
Lu, J
Kobayashi, H
Kennedy, R
Celis, E
机构
[1] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN 55905 USA
[3] Mayo Clin, Mayo Grad Sch, Rochester, MN 55905 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The survival and proliferation of CTL during the effector phase of the immune response is critical for the elimination of infectious agents and tumor cells. We report here that in an in vitro model system, the expansion and cytolytic function of tumor-reactive human CTL can be enhanced by CD4(+) helper T lymphocytes through costimulatory signals that are mediated by cell surface molecules. The results presented here suggest that costimulatory receptors on CTL such as CD27, CD134 (4-1BB), and MHC class 11 are capable of directly interacting with the corresponding ligands on T-helper lymphocytes resulting in enhanced proliferation and survival of the CTL during the effector phase of antitumor immune responses. These findings underline the importance of antigen-specific helper T lymphocytes for the regulation and maintenance of CTL immunity, and have implications for the design of therapeutic vaccines for cancer.
引用
收藏
页码:922 / 931
页数:10
相关论文
共 50 条
  • [41] Mucin may not be the recognition antigen for autologous and heterologous pancreatic tumor-reactive T cells
    Selvan, RS
    10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, 1998, : 1123 - 1127
  • [42] Necrotic death but not irradiation abolishes costimulation of T-cell effector functions and survival by CD80-expressing tumor cells
    Stärck, L
    Scholz, C
    Blankenstein, T
    Dörken, B
    Daniel, PT
    INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (01) : 78 - 86
  • [43] CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
    Zhu, Yuwen
    Chen, Lieping
    CLINICAL CANCER RESEARCH, 2014, 20 (01) : 3 - 5
  • [44] The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells
    Kuczma, Michal P.
    Ding, Zhi-Chun
    Li, Tao
    Habtetsion, Tsadik
    Chen, Tingting
    Hao, Zhonglin
    Bryan, Locke
    Singh, Nagendra
    Kochenderfer, James N.
    Zhou, Gang
    ONCOTARGET, 2017, 8 (67) : 111931 - 111942
  • [45] Cancer-driven exhaustion of tumor-reactive γδ-T cells: Relevance to immunosurveillance and immunotherapy
    Beck, Benjamin H.
    Kim, Hyung-Gyoon
    Haines, Hilary
    Feeley, Kyle
    Lopez, Richard
    CANCER RESEARCH, 2010, 70
  • [46] Bim identifies tumor-reactive effector CD8+ T cells in cancer patients respond to anti-PD-1 therapy
    Dong, Haidong
    Dronca, Roxana S.
    JOURNAL OF IMMUNOLOGY, 2016, 196
  • [47] PROSTATE CANCER IMMUNOTHERAPY USING BI-SPECIFIC TUMOR-REACTIVE T CELLS
    Chan, Robert
    Leen, Ann
    Brenner, Malcolm
    Palapattu, Ganesh
    Vera, Juan
    JOURNAL OF UROLOGY, 2012, 187 (04): : E530 - E530
  • [48] Identification of novel altered peptide ligands recognized by human tumor-reactive T cells
    Fallahi, A
    Li, Y
    Pinilla, C
    Yee, C
    JOURNAL OF INVESTIGATIVE MEDICINE, 2006, 54 (01) : S88 - S88
  • [49] Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells
    Sachs, Abraham
    Moore, Eugene
    Kosaloglu-Yalcin, Zeynep
    Peters, Bjoern
    Sidney, John
    Rosenberg, Steven A.
    Robbins, Paul F.
    Sette, Alessandro
    JOURNAL OF IMMUNOLOGY, 2020, 205 (02): : 539 - 549
  • [50] Adoptive immunotherapy of cancer with hyper-expanded tumor-reactive T cells.
    Plautz, GE
    Wang, LX
    BLOOD, 2003, 102 (11) : 407B - 407B